Ovid Therapeutics – 8/25/2020

Ovid Therapeutics Inc. is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. The Company’s most clinically-advanced product candidate, OV101, is a first-in-class δ-selective GABAA receptor agonist. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company for the potential treatment of rare…

Ovid Therapeutics – 2/21/2019

Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. The Companys most clinically-advanced product candidate, OV101, is a first-in-class ?-selective GABAA receptor agonist. OV101 is currently Phase III ready in Angelman syndrome (AS). Ovid announced positive topline Phase II data in…

Ovid Therapeutics – 5/4/2017

Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda…

Ovid Therapeutics – 10/4/2019

Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda…

Ovid Therapeutics – 8/11/2015

Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain.  Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda…

Ovid Therapeutics – 6/1/2018

Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda…

CTI BioPharma – 8/25/2021

CTI BioPharma (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI focuses on developing…

Dynavax Technologies Corp – 5/22/2020

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel vaccines. Dynavax’s sole marketed product, HEPLISAV-B, was approved in November 2017 and launched in February 2018 for the prevention of infection caused by all known subtypes of Hepatitis B virus in adults age 18 years or older. Dynavax is…

Vir Biotechnology, Inc. – 7/8/2020

Vir Biotechnology, Inc. is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The Company has assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA. The Company’s current development pipeline consists of product candidates targeting severe…

Dynavax Technologies Corp – 8/6/2020

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.  Dynavax is also developing CpG 1018 as an advanced vaccine…

Icosavax, Inc. – 7/28/2021

Icosavax (the “Company”) is a biotechnology company developing virus-like particle (VLP) vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The Company’s VLP platform technology is designed to enable a multivalent, particle-based display of complex viral antigens, which could induce broad, robust and durable protection against the specific targeted virus. Icosavax’s…

Cue Health, Inc. – 9/23/2021

Cue Health Inc. (“Cue Health” or the “Company”) is a health technology company that has developed a platform consisting of the following hardware and software components: (1) the Cue Health Monitoring System, made up of a portable, durable and reusable reader, a single-use test cartridge, and a sample collection wand, (2) the Cue Data and…

Load More